Endothelial actions of atrial and B-type natriuretic peptides

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 522-531

  Kuhn, Michaela ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

angiogenesis; atrial natriuretic peptide; B type natriuretic peptide; cGMP; endothelial cells; guanylyl cyclase A; permeability

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; PHOSPHODIESTERASE III; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLOOD PRESSURE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CELL REGENERATION; CELL TYPE; ENDOTHELIUM CELL; GC A GENE; GENE; HEART MUSCLE CELL; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOXP SITE; LUNG CIRCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; ENDOTHELIUM, VASCULAR; HUMANS; LUNG; NATRIURETIC PEPTIDE, BRAIN; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, GUANYLATE CYCLASE-COUPLED;

EID: 84859902601     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01827.x     Document Type: Review

References (94)

1. Adamson RH, Ly JC, Sarai RK, Lenz JF, Altangerel A, Drenckhahn D, et al,. (2008). Epac/Rap1 pathway regulates microvascular hyperpermeability induced by PAF in rat mesentery. Am J Physiol 294: H1188-H1196. (Pubitemid 351468714)
2. Aicher A, Heeschen C, Feil S, Hofmann F, Mendelsohn ME, Feil R, et al,. (2009). cGMP-dependent protein kinase I is crucial for angiogenesis and postnatal vasculogenesis. PLoS ONE 4: e4879. Epub 16 March 2009.
3. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. Almeida FA, Suzuki M, Maack T, (1986). Atrial natriuretic factor increases hematocrit and decreases plasma volume in nephrectomized rats. Life Sci 39: 1193-1199. (Pubitemid 16017752)
5. Birukova AA, Zagranichnaya T, Alekseeva E, Bokoch GM, Birukov KG, (2008). Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J Cell Physiol 215: 715-724. (Pubitemid 351632693)
6. Birukova AA, Xing J, Fu P, Yakubov B, Dubrovskyi O, Fortune JA, et al,. (2010). Atrial natriuretic peptide attenuates LPS-induced lung vascular leak: role of PAK1. Am J Physiol 299: L652-L663.
7. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H, (1981). A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28: 89-94. (Pubitemid 11184926)
8. de Bold AJ, Ma KK, Zhang Y, de Bold ML, Bensimon M, Khoshbaten A, (2001). The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 79: 705-714. (Pubitemid 32745037)
9. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML, (1990). Diverse biological actions of atrial natriuretic peptide. Pharmacol Rev 70: 665-699. (Pubitemid 20196047)
10. Bruegger D, Jacob M, Rehm M, Loetsch M, Welsch U, Conzen P, et al,. (2005). Atrial natriuretic peptide induces shedding of endothelial glycocalyx in coronary vascular bed of guinea pig hearts. Am J Physiol 289: H1993-H1999. (Pubitemid 41507349)
11. Bryan PM, Potter LR, (2002). The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases. J Biol Chem 277: 16041-16047. (Pubitemid 34967888)
12. Chappell D, Jacob M, Rehm M, Stoeckelhuber M, Welsch U, Conzen P, et al,. (2009). The glycocalyx of the human umbilical vein endothelial cell. An impressive structure ex vivo but not in culture. Circ Res 104: 1313-1317.
13. Chen H, Levine YC, Golan DE, Michel T, Lin AJ, (2008). Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem 283: 4439-4447.
14. Chen W, Gassner B, Börner S, Nikolaev V, Schlegel N, Waschke J, et al,. (2012). Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc Res 93: 141-151.
15. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, et al,. (2001). Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A 98: 4016-4021. (Pubitemid 32249890)
16. Curry FR, (2005). Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume. J Clin Invest 115: 1458-1461.
17. Curry FR, Adamson RH, (2010). Vascular permeability modulation at the cell, microvessel, or whole organ level: towards closing gaps in our knowledge. Cardiovasc Res 87: 195-197.
18. Curry FR, Rygh CB, Karlsen T, Wiig H, Adamson RH, Clark JF, et al,. (2010). Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in mouse skeletal muscle and skin: role in regulation of plasma volume. J Physiol 588: 325-339.
19. De Vito P, Incerpi S, Pedersen JZ, Luly P, (2010). Atrial natriuretic peptide and oxidative stress. Peptides 31: 1412-1419.
20. Dodd-o JM, Hristopoulos ML, Kibler K, Gutkowska J, Mukaddam-Daher S, Gonzalez A, et al,. (2008). The role of natriuretic peptide receptor-A signaling in unilateral lung ischemia-reperfusion injury in the intact mouse. Am J Physiol Lung Cell Mol Physiol 294: L714-L723. (Pubitemid 351520104)
21. Doi K, Ikeda T, Itoh H, Ueyama K, Hosoda K, Ogawa Y, et al,. (2001). C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 21: 930-936. (Pubitemid 34168648)
22. Drewett JG, Garbers DL, (1994). The family of guanylyl cyclase receptors and their ligands. Endocr Rev 13: 135-162. (Pubitemid 24129181)
23. Ehret GB, the International Consortium for Blood Pressure Genome-Wide Association Studies (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103-109.
24. Flückiger JP, Waeber B, Matsueda G, Delaloye B, Nussberger J, Brunner HR, (1986). Effect of atriopeptin III on hematocrit and volemia of nephrectomized rats. Am J Physiol 251: H880-H883.
25. Fryer BH, Wang C, Vedantam S, Zhou GL, Jin S, Fletcher L, et al,. (2006). cGMP-dependent protein kinase phosphorylates p21-activated kinase (Pak) 1, inhibiting Pak/Nck binding and stimulating Pak/Vasodilator-stimulated phosphoprotein association. J Biol Chem 281: 11487-11495. (Pubitemid 43855404)
26. Fürst R, Brueckl C, Kuebler WM, Zahler S, Krötz F, Görlach A, et al,. (2005). Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ Res 96: 43-53. (Pubitemid 40095753)
27. Fürst R, Bubik MF, Bihari P, Mayer BA, Khandoga AG, Hoffmann F, et al,. (2008). Atrial natriuretic peptide protects against histamine-induced endothelial barrier dysfunction in vivo. Mol Pharmacol 74: 1-8. (Pubitemid 351872153)
28. Hirooka Y, Takeshita A, Imaizumi T, Suzuki S, Yoshida M, Ando S, et al,. (1990). Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation 82: 147-153. (Pubitemid 20216325)
29. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, et al,. (2002). Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A 99: 7142-7147. (Pubitemid 34526269)
30. Hong D, Jaron D, Buerk DG, Barbee KA, (2008). Transport-dependent calcium signaling in spatially segregated cellular caveolar domains. Am J Physiol Cell Physiol 294: C856-C866. (Pubitemid 351468694)
31. Imamura T, Ohnuma N, Iwasa F, Furuya M, Hayashi Y, Inomata N, et al,. (1988). Protective effect of alpha-human atrial natriuretic polypeptide (alpha-HANP) on chemical-induced pulmonary edema. Life Sci 42: 403-414. (Pubitemid 18066893)
32. Inomata N, Ohnuma N, Furuya M, Hayashi Y, Kanai Y, Ishihara T, et al,. (1987). Alpha-human atrial natriuretic peptide (alpha-HANP) prevents pulmonary edema induced by arachidonic acid treatment in isolated perfused lung from guinea pig. Jpn J Pharmacol 44: 211-214. (Pubitemid 17084360)
33. Irwin DC, Rhodes J, Baker DC, Nelson SE, Tucker A, (2001). Atrial natriuretic peptide blockade exacerbates high altitude pulmonary edema in endotoxin-primed rats. High Alt Med Biol 2: 349-360. (Pubitemid 33100442)
34. Irwin DC, Tissot van Patot MC, Tucker A, Bowen R, (2005a). Direct ANP inhibition of hypoxia-induced inflammatory pathways in pulmonary microvascular and macrovascular endothelial monolayers. Am J Physiol Lung Cell Mol Physiol 288: L849-L859. (Pubitemid 40547910)
35. Irwin DC, Patot MT, Tucker A, Bowen R, (2005b). Neutral endopeptidase null mice are less susceptible to high altitude-induced pulmonary vascular leak. High Alt Med Biol 6: 311-319. (Pubitemid 43137287)
36. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, et al,. (1995). Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267: 679-681.
37. Jouni H, Rodeheffer RJ, Kullo IJ, (2011). Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries. Arterioscler Thromb Vasc Biol 31: 197-202.
38. 2+ signaling and cytoskeletal reorganization. Circ Res 106: 1103-1116.
39. Kiemer AK, Vollmar AM, (2001). The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 60 (Suppl. 3): iii68-iii70. (Pubitemid 32980449)
40. Kiemer AK, Weber NC, Fürst R, Bildner N, Kulhanek-Heinze S, Vollmar AM, (2002). Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res 90: 874-881. (Pubitemid 34633879)
41. Kini V, Chavez A, Mehta D, (2010). A new role for PTEN in regulating transient receptor potential canonical channel 6-mediated Ca2+ entry, endothelial permeability, and angiogenesis. J Biol Chem 285: 33082-33091.
42. Klaiber M, Dankworth B, Kruse M, Hartmann M, Nikolaev VO, Völker K, et al,. (2011). A cardiac pathway of Cyclic GMP-independent signalling of guanylyl cyclase A, the receptor for atrial natriuretic peptide. Proc Natl Acad Sci U S A 108: 18500-18505.
43. Klinger JR, Warburton R, Carino GP, Murray J, Murphy C, Napier M, et al,. (2006). Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. Exp Cell Res 312: 401-410. (Pubitemid 41804105)
44. Koika V, Zhou Z, Vasileiadis I, Roussos C, Finetti F, Monti M, et al,. (2010). PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis. Vascul Pharmacol 53: 215-222.
45. Komarova Y, Malik AB, (2010). Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol 72: 463-493.
46. Kook H, Itoh H, Choi BS, Sawada N, Doi K, Hwang TJ, et al,. (2003). Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. Am J Physiol 284: H1388-H1397. (Pubitemid 36348603)
47. Kuhn M, (2003). Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93: 700-709. (Pubitemid 37288664)
48. Kuhn M, Völker K, Schwarz K, Carbajo-Lozoya J, Flögel U, Jacoby C, et al,. (2009). The natriuretic peptide/guanylyl cyclase-a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest 119: 2019-2030.
49. Lara-Castillo N, Zandi S, Nakao S, Ito Y, Noda K, She H, et al,. (2009). Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. Am J Pathol 175: 2343-2350.
50. Lin YC, Samardzic H, Adamson RH, Renkin EM, Clark JF, Reed RK, et al,. (2011). Phosphodiesterase 4 inhibition attenuates atrial natriuretic peptide-induced vascular hyperpermeability and loss of plasma volume. J Physiol 589: 341-353.
51. Lin YC, Adamson RH, Clark JF, Reed RK, Curry F-RE, (2012). Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice. J Physiol 590: 309-322.
52. Lofton CE, Baron DA, Heffner JE, Currie MG, Newman WH, (1991). Atrial natriuretic peptide inhibits oxidant-induced increases in endothelial permeability. J Mol Cell Cardiol 23: 919-927.
53. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, et al,. (1995). Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378: 65-68.
54. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, et al,. (1999). The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A 96: 7403-7408. (Pubitemid 29299674)
55. McKie PM, Sangaralingham SJ, Burnett JC Jr, (2010). CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep 7: 93-99.
56. Mehta D, Malik AB, (2006). Signalling mechanisms regulating endothelial permeability. Physiol Rev 86: 279-367.
57. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Amaha K, (1998). Beneficial effects of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest 114: 223-228. (Pubitemid 28337387)
58. Murthy KS, Teng BQ, Zhou H, Jin JG, Grider JR, Makhlouf GM, (2000). G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am J Physiol 278: G974-G980. (Pubitemid 30439177)
59. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al,. (2009). Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 41: 666-676.
60. Opgenorth TJ, Budzik GP, Mollison KW, Davidsen SK, Holst MR, Holleman WH, (1990). Atrial peptides induce mast cell histamine release. Peptides 11: 1003-1007. (Pubitemid 20337199)
61. Park K, Itoh H, Yamahara K, Sone M, Miyashita K, Oyamada N, et al,. (2008). Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology 149: 483-491. (Pubitemid 351159359)
62. Pedram A, Razandi M, Levin ER, (2001). Natriuretic peptide suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology 142: 1578-1586. (Pubitemid 32299687)
63. Pedram A, Razandi M, Levin ER, (2002). Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide. J Biol Chem 277: 44385-44398. (Pubitemid 36157874)
64. Riegger GA, Elsner D, Forssmann WG, Kromer EP, (1990). Effects of ANP-(95-126) in dogs before and after induction of heart failure. Am J Physiol 259: H1643-H1648.
65. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, et al,. on behalf of the SUPER-2 study group (2011). Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 140: 1274-1283.
66. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, et al,. (2005). Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115: 1666-1674. (Pubitemid 40814676)
67. Sakamoto Y, Mashiko K, Saito N, Matsumoto H, Hara Y, Kutsukata N, et al,. (2010). Effectiveness of human atrial natriuretic peptide supplementation in pulmonary edema patients using the pulse contour cardiac output system. Yonsei Med J 51: 354-359.
68. Schreier B, Börner S, Völker K, Gambaryan S, Schäfer SC, Kuhlencordt P, et al,. (2008). The heart communicates with the endothelium through the guanylyl cyclase-A receptor: acute handling of intravascular volume in response to volume expansion. Endocrinology 149: 4193-4199.
69. Schröter J, Zahedi RP, Hartmann M, Gassner B, Gazinski A, Waschke J, et al,. (2010). Homologous desensitization of guanylyl cyclase A, the receptor for atrial natriuretic peptide, is associated with a complex phosphorylation pattern. FEBS J 277: 2440-2453.
70. Scott RS, Rentsendorj O, Servinsky LE, Moldobaeva A, Damico R, Pearse DB, (2010). Cyclic GMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 299: L323-L333.
71. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Bürger A, et al,. (2005). Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105: 3569-3576. (Pubitemid 40628202)
72. Shmilovich H, Ben-Shoshan J, Ral R, Afek A, Barshack I, Maysel-Auslander S, et al,. (2009). B-type natriuretic peptide enhances vasculogenesis by promoting number and functional properties of early endothelial progenitor cells. Tissue Eng 15: 2741-2749.
73. Skryabin BV, Holtwick R, Fabritz L, Kruse MN, Veltrup I, Stypmann J, et al,. (2004). Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by alphaMHC-Cre-mediated recombination. Genesis 39: 288-298. (Pubitemid 39201551)
74. Smolenski A, Poller W, Walter U, Lohmann SM, (2000). Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I. J Biol Chem 275: 25723-25732.
75. Surapisitchat J, Beavo JA, (2011). Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases. Handb Exp Pharmacol 204: 193-210.
76. Surapisitchat J, Jeon K-I, Yan C, Beavo JA, (2007). Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res 101: 811-818. (Pubitemid 350287196)
77. Takahashi S, Lin H, Geshi N, Mori Y, Kawarabayashi Y, Takami N, et al,. (2008). Nitric oxide-cGMP-protein kinase G pathway negatively regulates vascular transient receptor potential channel TRPC6. J Physiol 586: 4209-4223.
78. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al,. (2000). Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 97: 4239-4244. (Pubitemid 30226117)
79. Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL, (2004). Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. Proc Natl Acad Sci U S A 101: 17300-17305. (Pubitemid 39627814)
80. Toshimori H, Nakazato M, Toshimori K, Asai J, Matsukura S, Oura C, et al,. (1988). Distribution of atrial natriuretic polypeptide (ANP)-containing cells in the rat heart and pulmonary vein. Immunohistochemical study and radioimmunoassay. Cell Tissue Res 251: 541-546. (Pubitemid 18060088)
81. Trippodo NC, Barbee RW, (1987). Atrial natriuretic factor decreases whole-body capillary absorption in rats. Am J Physiol 252: R915-R920.
82. Tsukagoshi H, Shimizu Y, Kawata T, Hisada T, Shimizu Y, Iwamae S, et al,. (2001). Atrial natriuretic peptide inhibits tumor necrosis factor-alpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept 99: 21-29. (Pubitemid 32232124)
83. Tsutamoto T, Kanamori T, Wada A, Kinoshita M, (1992). Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 20: 541-546.
84. Tucker VL, Simanonok KE, Renkin EM, (1992). Tissue-specific effects of physiological ANP infusion on blood-tissue albumin transport. Am J Physiol 263: R945-R953.
85. de Visser YP, Walther FJ, Laghmani H, Boersma H, van der Laarse A, Wagenaar GT, (2009). Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 10: 30.
86. Vollmar AM, Förster R, Schulz R, (1997). Effects of atrial natriuretic peptide on phagocytosis and respiratory burst in murine macrophages. Eur J Pharmacol 319: 279-285. (Pubitemid 27056050)
87. Weidemann A, Klanke B, Wagner M, Volk T, Willam C, Wiesener MS, et al,. (2008). Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J 409: 233-242.
88. Wiedermann CJ, Niedermühlbichler M, Braunsteiner H, Widermann CJ, (1992). Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. J Clin Invest 89: 1580-1586.
89. Wilhide ME, Jones WK, (2006). Potential therapeutic gene for the treatment of ischemic disease: Ad2/hypoxia-inducible factor-1alpha (HIF-1)/VP16 enhances B-type natriuretic peptide gene expression via a HIF-1-responsive element. Mol Pharmacol 69: 1773-1778. (Pubitemid 43894292)
90. Xing J, Birukova AA, (2010). ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha. Microvasc Res 79: 56-62.
91. Xing J, Moldobaeva N, Birukova AA, (2011). Atrial natriuretic peptide protects against Staphylococcus aureus-induced lung injury and endothelial barrier dysfunction. J Appl Physiol 110: 213-224.
92. Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, Sawada N, et al,. (2003). Significance and therapeutical potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A 100: 3404-3409. (Pubitemid 36356596)
93. Yin J, Hoffmann J, Kaestle SM, Neye N, Wang L, Baeurle J, et al,. (2008). Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. Circ Res 102: 966-974. (Pubitemid 351591552)
94. Zhu B, Zhang L, Alexeyev M, Alvarez DF, Strada SJ, Stevens T, (2009). Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. Am J Physiol 296: L220-L228.